anti-BRCA2 (BRCA2) 抗体产品概述

Full name:
anti-Breast Cancer 2, Early Onset 抗体 (BRCA2)
在www.antibodies-online.cn可供89 Breast Cancer 2, Early Onset (BRCA2) 抗体的22不同的供货商。 再加上,我们可以发BRCA2 试剂盒 (24)BRCA2 蛋白 (2)和数多这个蛋白质的别的产品。 总共118 BRCA2产品已列进来了。
别名:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
列出全部抗体 基因 基因ID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

显示所有的来源

显示所有的同义词

最受欢迎的抗anti-BRCA2 (BRCA2) 抗体

选择您的来源和应用

抗Mouse (Murine) BRCA2 抗体:

抗Human BRCA2 抗体:

抗Rat (Rattus) BRCA2 抗体:

所有可销售的anti-BRCA2 抗体

您会转到已过滤好的搜索

引用最多的anti-BRCA2 抗体

  1. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (p) - ABIN445491 : Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. in The Journal of biological chemistry 2000 (PubMed)
    Show all 2 references for 445491

  2. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN445493 : Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001 (PubMed)
    Show all 2 references for 445493

  3. Human Polyclonal BRCA2 Primary Antibody for IHC, ELISA - ABIN1533759 : Wooster, Bignell, Lancaster, Swift, Seal, Mangion, Collins, Gregory, Gumbs, Micklem: Identification of the breast cancer susceptibility gene BRCA2. in Nature 1996 (PubMed)
    Show all 2 references for 1533759

  4. Human Polyclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN4285196 : Moeller, Yordy, Williams, Giri, Raju, Molkentine, Byers, Heymach, Story, Lee, Sturgis, Weber, Garden, Ang, Schwartz: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. in Clinical cancer research : an official journal of the American Association for Cancer Research 2011 (PubMed)

更多抗BRCA2的相互作用对抗体

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (显示 TP53 抗体) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  2. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (显示 PALB2 抗体) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (显示 PALB2 抗体) and Trp53 (显示 TP53 抗体) heterozygosity .

  3. Merit40 (显示 BABAM1 抗体) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (显示 FANCD2 抗体) mutation.

  4. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  5. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  6. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (显示 PARP1 抗体) inhibition.

  7. BRCA2-mediated sequestration of nuclear RAD51 (显示 RAD51 抗体) serves to prevent inappropriate DNA interactions.

  8. BRCA2 directly represses the expression of IFN-related genes

  9. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  10. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. This study detected monoallelic L1053X mutation causing the same stop codon in BRCA2 protein sequence at the same position in four Sudanese female breast cancer patients out of nine from different families.

  2. Being a male BRCA1 or a BRCA2 mutation carrier or even being clinically defined as having high cancer risk with no known BRCA mutation in men is not associated with any clinically significant risk for developing this rare entity.

  3. A patient with an ampulla of Vater carcinoma was incidentally found to carry the BRCA2 c.156_157insAlu mutation. Further testing of a consecutive series of additional 15 ampullary carcinomas for BRCA1/BRCA2 mutations using a combination of direct founder mutation testing and full gene analysis with next generation sequencing. BRCA2 mutations were observed with a frequency of 14.3% in ampulla of Vater carcinomas.

  4. data from our systematic review and meta-analysis suggests a causal relationship between germline BRCA1/2-pathogenic mutations and the development of Uterine serous carcinoma.

  5. study demonstrates that the individual and combined expression patterns of the DDR (显示 DDR1 抗体) molecules PARP1 (显示 PARP1 抗体), gammaH2AX (显示 H2AFX 抗体), BRCA1, and BRCA2 could be predictive of the prognosis of STS (显示 STS 抗体) patients and suggests that controlling the activity of these DDR (显示 DDR1 抗体) molecules could be employed in new therapeutic stratagems for the treatment of STS (显示 STS 抗体)

  6. radiosensitization was evaluated using the glioblastoma cell line, U87MG-E6, which harbors inactivated p53 (显示 TP53 抗体), in comparison with the cell line, HCT116 p53 (显示 TP53 抗体) (-/-). We conclude that radiosensitization by arsenite is related to ROS (显示 ROS1 抗体) and BRCA2 function.

  7. Data suggest that RAD51 (显示 RAD51 抗体), BRCA2, and BRCA1 promote stability of nascent DNA at replication forks; RAD51 (显示 RAD51 抗体) prevents MRE11 (显示 MRE11A 抗体) nuclease (显示 DCLRE1C 抗体)-mediated degradation of nascent ssDNA; BRCA2 displaces RPA (显示 RPA1 抗体) (replication protein A (显示 GPR153 抗体)) complex by recruiting RAD51 (显示 RAD51 抗体) to protect ssDNA; BRCA1 promotes repair foci following DNA damage and is essential for cell survival. (BRCA = breast cancer recombination protein; RAD51 (显示 RAD51 抗体) = Rad51 (显示 RAD51 抗体) recombinase (显示 RAG1 抗体)) [REVIEW]

  8. we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.

  9. Data suggest that modulation of histone deacetylase (显示 HDAC1 抗体) (HAT (显示 MGEA5 抗体)) activity by an SNP in BRCA2 (breast cancer type 2 susceptibility protein; rs144848, 1342A>C, N372H) is a plausible mechanism of paclitaxel resistance in breast cancer; after HAT (显示 MGEA5 抗体) inhibitor treatment, HAT (显示 MGEA5 抗体) activity, and paclitaxel sensitivity is restored in heterozygous BRCA2 variant breast cancer cells.

  10. One rare variant in BRCA2 3'UTR (显示 UTS2R 抗体) was identified in 716 breast cancer cases and 619 controls. Identified variant gives no convincing evidence of potential pathogenicity.

BRCA2 抗原简介

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) 抗体
  • breast cancer 2, early onset (brca2) 抗体
  • breast cancer 2 (Brca2) 抗体
  • breast cancer 2, early onset (Brca2) 抗体
  • AI256696 抗体
  • AW045498 抗体
  • BRCA2 抗体
  • BRCC2 抗体
  • BROVCA2 抗体
  • FACD 抗体
  • FAD 抗体
  • FAD1 抗体
  • FANCB 抗体
  • FANCD 抗体
  • FANCD1 抗体
  • GLM3 抗体
  • PNCA2 抗体
  • RAB163 抗体

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
anti-BRCA2 (BRCA2) 抗体 精选生产商
您还需要查找其他产品吗?